Targeted exosomes for co-delivery of siFGL1 and siTGF-β1 trigger combined cancer immunotherapy by remodeling immunosuppressive tumor microenvironment

Pei, Xing; Zhang, Xiaojuan; Zhang, Lu; Yuan, Mengmeng; Sun, Lu; Yu, Fei; Wang, Bangmao; Zhao, Jingwen; He, Huining; Yang, Victor C.

doi:10.1016/j.cej.2021.129774

Cited by 24 publications

(13 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B Exosomes co-delivery chemotherapy drugs oxaliplatin (OXA) and nucleic acid drugs gal-9 siRNA to enhancing immunotherapy and reprogramming tumor microenvironment (TME) [ 100 ]. C cRGD-modified exosome with high siFGL1 and siTGF-β1 loading efficiency to realize the co-silence of FGL1 and TGF-β1 to to block immune checkpoints and simultaneously regulate TME [ 150 ] …”

Section: Exosomes-based Nucleic Acid Delivery System For Cancer Treat...mentioning

confidence: 99%

“…6 B). Furthermore, Pei et al [ 150 ] established a cRGD-modified exosome with fibrinogen-like protein 1 (FGL1, an important immune checkpoint) siRNA and transforming growth factor-β (TGF-β1, an immunosuppressive cytokine in TME) siRNA (cRGD-Exo/siMix) to co-silence of FGL1 and TGF-β1. The results revealed that FGL1 expression was inhibited, which activated T cell recognition.…”

Section: Exosomes-based Nucleic Acid Delivery System For Cancer Treat...mentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in exosome-mediated nucleic acid delivery for cancer therapy

et al. 2022

View full text Add to dashboard Cite

Cancer is a leading public health problem worldwide. Its treatment remains a daunting challenge, although significant progress has been made in existing treatments in recent years. A large concern is the poor therapeutic effect due to lack of specificity and low bioavailability. Gene therapy has recently emerged as a powerful tool for cancer therapy. However, delivery methods limit its therapeutic effects. Exosomes, a subset of extracellular vesicles secreted by most cells, have the characteristics of good biocompatibility, low toxicity and immunogenicity, and great designability. In the past decades, as therapeutic carriers and diagnostic markers, they have caught extensive attention. This review introduced the characteristics of exosomes, and focused on their applications as delivery carriers in DNA, messenger RNA (mRNA), microRNA (miRNA), small interfering RNA (siRNA), circular RNA (circRNA) and other nucleic acids. Meanwhile, their application in cancer therapy and exosome-based clinical trials were presented and discussed. Through systematic summarization and analysis, the recent advances and current challenges of exosome-mediated nucleic acid delivery for cancer therapy are introduced, which will provide a theoretical basis for the development of nucleic acid drugs. Graphical Abstract

show abstract

Section: Exosomes-based Nucleic Acid Delivery System For Cancer Treat...mentioning

confidence: 99%

Section: Exosomes-based Nucleic Acid Delivery System For Cancer Treat...mentioning

confidence: 99%

Recent advances in exosome-mediated nucleic acid delivery for cancer therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Recently, exosomes from tumor cells, adipose stem cells, mesenchymal stem cells and epithelial cells have been used to treat different diseases (Zhang M. et al, 2021;Pan et al, 2021;Rui et al, 2021;Sun et al, 2021;Wang L. et al, 2022). Gene therapy has shown great promise in treating intractable diseases (Suresh et al, 2014).…”

Section: Nucleic Acid Drugsmentioning

confidence: 99%

“…In addition, the natural materials-derived biocompatibility, structural stability, good permeability, low toxicity, and immunogenicity make them ideal carriers for drug delivery ( Lee et al, 2012 ; Xin et al, 2012 ; Lou et al, 2015 ). Increased studies have indicated the superior effect of drug-loaded exosomes in treating many diseases ( Bagheri et al, 2020 ; Pei et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Exosomes and mimics as novel delivery platform for cancer therapy

Yang

Wang²,

Guan³

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Exosomes are nano-sized biological extracellular vesicles transmitting information between cells and constituting a new intercellular communication mode. Exosomes have many advantages as an ideal drug delivery nanocarrier, including good biocompatibility, permeability, low toxicity, and low immunogenicity. Recently, exosomes have been used to deliver chemotherapeutic agents, natural drugs, nucleic acid drugs, and other antitumor drugs to treat many types of tumors. Due to the limited production of exosomes, synthetic exosome-mimics have been developed as an ideal platform for drug delivery. This review summarizes recent advances in the application of exosomes and exosome-mimics delivering therapeutic drugs in treating cancers.

show abstract

“…It is considered to be the most promising method in cancer treatment. In recent years, new tumor-targeted strategies have emerged, such as tumor-targeted drug therapy ( Jin et al, 2021 ; Kerns et al, 2021 ; Li et al, 2021 ; Li et al, 2021 ), immunotherapy ( Chen et al, 2021 ; Lu et al, 2021 ; Pei et al, 2021 ), gene therapy ( Chada et al, 2015 ; Wang et al, 2021 ; Wang et al, 2021 ), virus therapy ( Kemler et al, 2021 ; Wan et al, 2021 ; Zhang et al, 2021 ), and cell-based targeted therapy ( Collet et al, 2016 ). Among them, tumor active targeted drug therapy based on nanoparticles (NPs) drug delivery systems achieved the most success.…”

Section: Introductionmentioning

confidence: 99%

Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy

Xiong¹,

Guo²,

Zeng³

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Dacarbazine (DTIC) dominates chemotherapy for malignant melanoma (MM). However, the hydrophobicity, photosensitivity, instability, and toxicity to normal cells of DTIC limit its efficacy in treating MM. In the present study, we constructed star-shaped block polymers nanoparticles (NPs) based on Cholic acid -poly (lactide-co-glycolide)-b-polyethylene glycol (CA-PLGA-b-PEG) for DTIC encapsulation and MM targeted therapy. DTIC-loaded CA-PLGA-b-PEG NPs (DTIC-NPs) were employed to increase the drug loading and achieve control release of DTIC, followed by further modification with nucleic acid aptamer AS1411 (DTIC-NPs-Apt), which played an important role for active targeted therapy of MM. In vitro, DTIC-NPs-Apt showed good pH-responsive release and the strongest cytotoxicity to A875 cells compared with DTIC-NPs and free DTIC. In vivo results demonstrated that the versatile DTIC-NPs-Apt can actively target the site of MM and exhibited excellent anti-tumor effects with no obvious side effects. Overall, this research provided multi-functional NPs, which endow a new option for the treatment of MM.

show abstract

Targeted exosomes for co-delivery of siFGL1 and siTGF-β1 trigger combined cancer immunotherapy by remodeling immunosuppressive tumor microenvironment

Cited by 24 publications

References 60 publications

Recent advances in exosome-mediated nucleic acid delivery for cancer therapy

Recent advances in exosome-mediated nucleic acid delivery for cancer therapy

Exosomes and mimics as novel delivery platform for cancer therapy

Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy

Contact Info

Product

Resources

About